New immunotherapy cocktail targets tough cancers
NCT ID NCT04021043
First seen Jan 05, 2026 · Last updated Jun 05, 2026 · Updated 22 times
Summary
This study tested a combination of three immunotherapy drugs (BMS-986156, ipilimumab, and nivolumab) with or without precise radiation therapy in 51 people with advanced lung, chest, or liver cancer that had spread. The goal was to find the safest doses and see if the treatment helps shrink tumors. While the approach aims to boost the immune system to fight cancer, it is not a cure and ongoing management is expected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.